September 15th 2025
The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.
September 13th 2025
September 12th 2025
September 11th 2025
Novel TKI Earns FDA Breakthrough Therapy Designation in HER2-Mutated NSCLC
February 26th 2024Preliminary findings from a phase 1 trial support the breakthrough therapy designation for BAY 2927088 as a treatment for those with unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.
Pembrolizumab/Chemo Gets EU Recommendation in Resectable NSCLC
February 23rd 2024The European Medicine Agency’s Committee for Medicinal Products for Human Use’s recommendation of approving pembrolizumab plus chemotherapy in resectable non–small cell lung cancer is based on results from the KEYNOTE-671 trial.
Osimertinib After CRT Yields PFS Benefit in EGFR-Mutated NSCLC
February 21st 2024Results from the phase 3 LAURA trial found a statistically significant PFS benefit and a positive trend in OS with osimertinib following chemoradiotherapy in patients with stage III EGFR-mutated non–small cell lung cancer.
Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%
February 20th 2024Dr. Gregory Gan introduces Case 2, featuring an 82-year-old former smoker with poorly differentiated lung adenocarcinoma and a PD-L1 level of 85%, initiating a conversation on the role of a multidisciplinary approach to treatment and consideration factors for surgical and radiotherapy interventions.
Selecting Novel Small-Molecule Agents Vs Chemotherapy in KRAS G12C+ NSCLC
February 14th 2024Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy
February 13th 2024Dr. Reddy offers expert insights on employing concurrent immunotherapy with chemoradiotherapy, discussing the approach's role and drawing from recent data, such as results from the KEYNOTE-799, PACIFIC-6, and DOLPHIN studies, to inform treatment strategies.
The Potential Role of Combination Adjuvant Immunotherapy in NSCLC
February 6th 2024A group of experts in oncology investigates the feasibility of combination adjuvant immunotherapy in NSCLC consolidation, assessing the utilization of multiple immune checkpoint inhibitors and scrutinizing the rationale, with a focus on findings from the COAST study and PACIFIC-8 studies.
Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC
January 30th 2024A panel of oncology experts examine the role of consolidation immunotherapy in patients receiving concurrent chemoradiotherapy for unresectable Stage-III NSCLC, discussing 5-year survival outcomes from the PACIFIC trial, the impact on institutional treatment approaches, criteria for selecting patients for consolidation durvalumab, the significance of baseline scans, as well as exploring real-world evidence on consolidation durvalumab.
Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC
January 30th 2024Krishna Reddy, MD, PhD, explores the roles of sequential and concurrent chemoradiotherapy (sCRT and cCRT) in patients with unresectable stage III NSCLC, delving into considerations for selecting between the two approaches and examining potential variations in treatment based on factors such as age, performance status (PS), or comorbidities.